About the Company
We do not have any company description for Novus Therapeutics Inc at the moment.
Please visit http://novustherapeutics.com/ for more information about the company.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NVUS News
Jon Kuwahara's Net Worth
This is based on reported shares across multiple companies, which include EMMAUS LIFE SCIENCES, INC., and Novus Therapeutics, Inc.. Attention insiders: Dive deeper into market movements and stay ...
EFTR eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...
Ovid Therapeutics Inc OVID
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
ONTX Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage ...
Kintara Therapeutics Inc KTRA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.
Coeptis Therapeutics Holdings Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders are probably feeling a little disappointed, since its shares fell 5.9% to US$26.10 in the week after its latest full-year results.
Viking Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...